Abstract
Alzheimer's (AD) and Parkinson's (PD) diseases are some of the most debilitating neurodegenerative pathologies. Sadly, the current pharmacotherapy consists of drugs with limited potential administered to restore relevant neurotransmitter systems, such as acetylcholinesterase inhibitors blocking the enzyme responsible for the metabolizing acetylcholine in AD and L-dopa and other agents tha…